Dr. Raymond Douglas is honored to announce that his new study Teprotumumab for Thyroid-Associated Ophthalmopathy has been published in the New England Journal of Medicine. The FDA has designated this drug as a “breakthrough” therapy. This designation is only given to a couple of drugs each year and is reserved for drugs that are so important and beneficial to changing the field of treatment for patients. Dr. Douglas was the principle investigator of all the research centers and the trial. Twenty-two centers were involved and this represents the largest trial of biologic ever in this disease.

Graves’ Disease affects nearly 10 million Americans and results in severe bulging of the eyes. If you are among those with the disease or know someone who is, new hope has arrived from Temprotumumab.

This is the first medicine that can take the place of surgery for thyroid eye disease patients and is the first and only medicine that has ever been shown to reverse the disease. Dr. Douglas will be directing continued trials in Los Angeles (the only center on the West Coast).

To find out more information, call us today at 310-657-4302.

For those patients who are located outside of Southern California, Dr. Douglas offers Skype consultations so that you can learn more about the therapy and find out if you are a candidate for the treatment from the comfort of your own home. When you call Dr. Douglas’ office, just ask for more information about Skype consultations.

Watch Dr. Douglas Discuss Temprotumumab